- |||||||||| Mekinist (trametinib) / Novartis
Review, Journal: "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). (Pubmed Central) - Jul 23, 2022 Using the screening systems for agents that up-regulate the expression of p15, p27, and p21, we discovered the novel MEK inhibitor trametinib, the novel RAF/MEK inhibitor CH5126766/RO5126766/VS-6766, and the histone deacetylase inhibitor YM753/OBP-801, respectively...The combination of trametinib and the BRAF inhibitor dabrafenib was approved for advanced BRAF mutant melanoma in the USA, EU, Japan, and many other countries...In 2018, this combination was also approved for locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer in the USA after it had been granted Breakthrough Therapy Designation by the FDA. I describe here the characterization of our original screening system, RB-reactivator screening, by which these three molecular-targeting agents that advanced into clinical trials were identified.
- |||||||||| spiruchostatin A (OBP-801) / Oncolys BioPharma
Journal: The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. (Pubmed Central) - Dec 17, 2020 The present results demonstrated that OBP-801 exerted therapeutic effects in myxofibrosarcoma in both single and concomitant administrations. Therefore, OBP-801 has potential as a novel treatment for myxofibrosarcoma.
- |||||||||| spiruchostatin A (OBP-801) / Oncolys BioPharma
Trial completion date, Trial primary completion date, Metastases: A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 13, 2019 P1a, N=17, Active, not recruiting, These results suggested that a combined treatment with OBP‑801 and amrubicin may have potential as a therapeutic strategy for SQCLC. Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Jun 2019
- |||||||||| spiruchostatin A (OBP-801) / Oncolys BioPharma
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date, Metastases: A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 17, 2018 P1a, N=17, Active, not recruiting, Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1a | N=36 --> 17 | Trial primary completion date: Feb 2017 --> Aug 2018
|